A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Lotiglipron (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 12 Dec 2023 Status changed from completed to discontinued.
- 18 Jul 2023 Planned End Date changed from 16 Oct 2023 to 25 Jul 2023.
- 18 Jul 2023 Planned primary completion date changed from 16 Oct 2023 to 25 Jul 2023.